NetworkNewsBreaks – Interpace Diagnostics (NASDAQ: IDXG) Receives European Patent Approval For Core Technology of its ThyraMIR® microRNA Classifier
Interpace Diagnostics (NASDAQ: IDXG) shares are up 7% after the company said this morning that the European Patent Office granted it a patent for use of microRNAs for distinguishing benign from malignant thyroid neoplasms. This patent covers the underlying technology of the company's ThyraMIR® microRNA Classifier. Interpace intends to validate and enforce this Intellectual Property in select European countries going forward. "We are pleased to announce the approval of this patent by the European Patent Office as it provides a basis for introducing our first product to the European market as part of our international expansion plan. Importantly, this patent…
